Literature DB >> 14960353

Close anatomical associations between beta-endorphin and luteinizing hormone-releasing hormone neuronal systems in the human diencephalon.

B Dudás1, I Merchenthaler.   

Abstract

Endogenous opiates, such as beta-endorphin, inhibit the release of luteinizing hormone (LH) release in the pituitary gland of several species including rat, pig, sheep, and human. Although it is generally believed that beta-endorphin influences gonadal functions via the regulation of hypothalamic LH-releasing hormone (LHRH) release, the morphological substrate underlying this regulation in humans remains elusive. In the present series of experiments the beta-endorphin-immunoreactive (IR) and LHRH-IR neural elements, utilizing single label immunohistochemistry, were mapped. Following the superimposition of the maps of these systems, the overlapping sites were identified and examined in order to verify the putative juxtapositions between the beta-endorphin-IR and LHRH-IR structures. LHRH-IR elements were detected mainly in the medial basal hypothalamus, in the medial preoptic area and along the diagonal band of Broca. Beta-endorphin-IR perikarya were observed in the infundibular region/median eminence, whereas beta-endorphin-IR axon varicosities were detected periventricularly in the preoptic and tuberal regions, in the medial basal hypothalamus and around the mamillary bodies. Careful examination of the immunoreactive elements in the overlapping areas revealed close contacts between beta-endorphin-IR and LHRH-IR structures, which have been verified in semithin plastic sections. These putative beta-endorphin-LHRH juxtapositions were most numerous in the medial preoptic area and in the infundibulum/median eminence of the human diencephalon. In conclusion, the present paper is the first study that revealed close juxtapositions between the beta-endorphin-IR and LHRH-IR neural elements in the human diencephalon. These beta-endorphin-LHRH contacts may be functional synapses, and they may be the morphological substrate of the beta-endorphin control on gonadal functions in man.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14960353     DOI: 10.1016/j.neuroscience.2003.11.021

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  6 in total

1.  Sex differences in acute hormonal and subjective response to naltrexone: The impact of menstrual cycle phase.

Authors:  Daniel J O Roche; Andrea C King
Journal:  Psychoneuroendocrinology       Date:  2014-10-30       Impact factor: 4.905

2.  Β-endorphin-immunoreactive perikarya appear to receive innervation from NPY-immunoreactive fiber varicosities in the human hypothalamus.

Authors:  Bertalan Dudas; Istvan Merchenthaler
Journal:  Brain Struct Funct       Date:  2021-10-29       Impact factor: 3.270

3.  Resistance training reduced luteinising hormone levels in postmenopausal women in a substudy of a randomised controlled clinical trial: A clue to how resistance training reduced vasomotor symptoms.

Authors:  Sigrid Nilsson; Moa Henriksson; Emilia Berin; David Engblom; Anna-Clara Spetz Holm; Mats Hammar
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

4.  Dynorphin immunoreactive fibers contact GnRH neurons in the human hypothalamus.

Authors:  Stephanie K Dahl; Marcel Amstalden; Lique Coolen; Maureen Fitzgerald; Michael Lehman
Journal:  Reprod Sci       Date:  2009-05-27       Impact factor: 3.060

Review 5.  Afferent neuronal control of type-I gonadotropin releasing hormone neurons in the human.

Authors:  Erik Hrabovszky; Zsolt Liposits
Journal:  Front Endocrinol (Lausanne)       Date:  2013-09-20       Impact factor: 5.555

6.  Lateral hypothalamic orexin and melanin-concentrating hormone neurons provide direct input to gonadotropin-releasing hormone neurons in the human.

Authors:  Katalin Skrapits; Vivien Kanti; Zsófia Savanyú; Csilla Maurnyi; Ottó Szenci; András Horváth; Beáta Á Borsay; László Herczeg; Zsolt Liposits; Erik Hrabovszky
Journal:  Front Cell Neurosci       Date:  2015-09-04       Impact factor: 5.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.